Format

Send to

Choose Destination
Yonsei Med J. 2018 Jan;59(1):72-79. doi: 10.3349/ymj.2018.59.1.72.

Effectiveness and Safety of Biolimus A9™-Eluting stEnt in Patients with AcUTe Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study).

Author information

1
Division of Cardiology, Department of Internal Medicine, Chosun University Hospital, Gwangju, Korea.
2
Division of Cardiology, Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea. myungho@chollian.net.
3
Division of Cardiology, Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea.
4
Division of Cardiology, Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, Korea.
5
Division of Cardiology, Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea.
6
Division of Cardiology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea.
7
Division of Cardiology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.
8
Division of Cardiology, Department of Internal Medicine, Presbyterian Medical Center, Jeonju, Korea.
9
Division of Cardiology, Department of Internal Medicine, Yeungnam University Hospital, Daegu, Korea.
10
Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
11
Division of Cardiology, Department of Internal Medicine, Konyang University Hospital, Daejeon, Korea.
12
Division of Cardiology, Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, Korea.
13
Division of Cardiology, Department of Internal Medicine, Wonkwang University Hospital, Iksan, Korea.
14
Division of Cardiology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
15
Division of Cardiology, Department of Internal Medicine, Gwangju Christian Hospital, Gwangju, Korea.
16
Division of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
17
Division of Cardiology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.
18
Division of Cardiology, Department of Internal Medicine, Saint Carollo Hospital, Suncheon, Korea.
19
Division of Cardiology, Department of Internal Medicine, Pusan National University Hospital, Busan, Korea.
20
Division of Cardiology, Department of Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea.
21
Division of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.
22
Division of Cardiology, Department of Internal Medicine, Gwangju Veterans Hospital, Gwangju, Korea.
23
Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea.

Abstract

PURPOSE:

This study sought to determine the 1-year clinical effectiveness and safety of a biodegradable, polymer-containing Biolimus A9™-eluting stent (BES) in Korean patients with acute coronary syndrome (ACS).

MATERIALS AND METHODS:

A total of 1000 ACS patients with 1251 lesions who underwent implantation of BESs at 22 centers in Korea were enrolled between May 2011 and July 2013. We assessed major adverse cardiac events (MACE) defined as the composite of cardiac death, non-fatal myocardial infarction (MI), and clinical-driven target vessel revascularization at 12 months.

RESULTS:

Patient mean age was 62.6±11.4 years. 72.8% of the patients were male, 28.5% had diabetes, 32.8% had multi-vessel disease (MVD), and 47.9% presented with acute MI (AMI). The mean global registry of acute coronary events risk score of all patients was 103.0±27.6. The number of stents per patient was 1.3±0.6. The incidences of MACE and definite stent thrombosis at 12 months were 3.9% and 0.2%, respectively. On multivariate Cox-regression analysis, age ≥65 years was identified as an independent predictors of 1-year MACE (hazard ratio=2.474; 95% confidence interval=1.202-5.091). Subgroup analyses revealed no significant differences in the incidence of MACE between patients with and without diabetes (4.3% vs. 3.7%, p=0.667), between those who presented with and without AMI (4.4% vs. 3.4%, p=0.403), and between those with and without MVD (4.6% vs. 3.5%, p=0.387).

CONCLUSION:

Our study demonstrated excellent 1-year clinical outcomes of BES implantation in patients at low-risk for ACS.

KEYWORDS:

Biolimus-eluting stent; acute coronary syndrome; biodegradable polymer

PMID:
29214779
PMCID:
PMC5725367
DOI:
10.3349/ymj.2018.59.1.72
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Yonsei University College of Medicine Icon for PubMed Central
Loading ...
Support Center